Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sagimet Biosciences Inc (SGMT) Fair Value & Analysis

Healthcare · US · Market cap $438M

Price$7.06
Fair Value$8.19
Upside+16.0%
Quality95/100
Evidence: Low Range $6.14 – $10.24

Fair value as of: Jun 24, 2026

Analysis

Sagimet Biosciences Inc (SGMT) currently trades at $7.06, while our model-based Fair Value estimate is $8.19 — implying the stock looks roughly 16.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Sagimet Biosciences Inc (SGMT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $8.19 versus a price of $7.06 — about +16% (undervalued). Model-based estimate, not financial advice.
What is the fair value of SGMT?
Our 21-model fair value for Sagimet Biosciences Inc is $8.19 (as of Jun 24, 2026), built from audited fundamentals. The current price is $7.06.
What is the quality score of SGMT?
Sagimet Biosciences Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.